Huybrechts Y, Mortier G, Boudin E, Van Hul W (2020) WNT signaling and bone: lessons from skeletal dysplasias and disorders. Front Endocrinol (Lausanne) 11:165

Article  PubMed  Google Scholar 

Bergen DJM, Maurizi A, Formosa MM, McDonald GLK, El-Gazzar A, Hassan N, Brandi ML, Riancho JA, Rivadeneira F, Ntzani E, Duncan EL, Gregson CL, Kiel DP, Zillikens MC, Sangiorgi L, Hogler W, Duran I, Makitie O, Van Hul W, Hendrickx G (2023) High bone mass disorders: new insights from connecting the clinic and the bench. J Bone Miner Res 38:229–247

Article  PubMed  Google Scholar 

Hamersma H, Gardner J, Beighton P (2003) The natural history of sclerosteosis. Clin Genet 63:192–197

Article  PubMed  CAS  Google Scholar 

Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M, Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF, Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C, Lindpaintner K, Vickery B, Foernzler D, Van Hul W (2001) Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10:537–543

Article  PubMed  CAS  Google Scholar 

Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulligan J (2001) Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet 68:577–589

Article  PubMed  PubMed Central  CAS  Google Scholar 

Leupin O, Piters E, Halleux C, Hu S, Kramer I, Morvan F, Bouwmeester T, Schirle M, Bueno-Lozano M, Fuentes FJ, Itin PH, Boudin E, de Freitas F, Jennes K, Brannetti B, Charara N, Ebersbach H, Geisse S, Lu CX, Bauer A, Van Hul W, Kneissel M (2011) Bone overgrowth-associated mutations in the LRP4 gene impair sclerostin facilitator function. J Biol Chem 286:19489–19500

Article  PubMed  PubMed Central  CAS  Google Scholar 

van Lierop AH, Hamdy NA, Hamersma H, van Bezooijen RL, Power J, Loveridge N, Papapoulos SE (2011) Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J Bone Miner Res 26:2804–2811

Article  PubMed  Google Scholar 

Ohkawara B, Cabrera-Serrano M, Nakata T, Milone M, Asai N, Ito K, Ito M, Masuda A, Ito Y, Engel AG, Ohno K (2014) LRP4 third beta-propeller domain mutations cause novel congenital myasthenia by compromising agrin-mediated MuSK signaling in a position-specific manner. Hum Mol Genet 23:1856–1868

Article  PubMed  CAS  Google Scholar 

Fijalkowski I, Geets E, Steenackers E, Van Hoof V, Ramos FJ, Mortier G, Fortuna AM, Van Hul W, Boudin E (2016) A novel domain-specific mutation in a sclerosteosis patient suggests a role of LRP4 as an anchor for sclerostin in human bone. J Bone Miner Res 31:874–881

Article  PubMed  CAS  Google Scholar 

Huybrechts Y, Boudin E, Hendrickx G, Steenackers E, Hamdy N, Mortier G, Martinez Diaz-Guerra G, Bracamonte MS, Appelman-Dijkstra NM, Van Hul W (2022) Identification of compound heterozygous variants in LRP4 demonstrates that a pathogenic variant outside the third beta-propeller domain can cause sclerosteosis. Genes (Basel) 13:80

Article  CAS  Google Scholar 

Choi HY, Dieckmann M, Herz J, Niemeier A (2009) Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4:e7930

Article  PubMed  PubMed Central  Google Scholar 

Xiong L, Jung JU, Wu H, Xia WF, Pan JX, Shen C, Mei L, Xiong WC (2015) Lrp4 in osteoblasts suppresses bone formation and promotes osteoclastogenesis and bone resorption. Proc Natl Acad Sci USA 112:3487–3492

Article  PubMed  PubMed Central  CAS  Google Scholar 

Kramer I, Loots GG, Studer A, Keller H, Kneissel M (2010) Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J Bone Miner Res 25:178–189

Article  PubMed  CAS  Google Scholar 

Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D, Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warmington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ, Lacey DL, Simonet WS, Ke HZ, Paszty C (2008) Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res 23:860–869

Article  PubMed  Google Scholar 

Boudin E, Yorgan T, Fijalkowski I, Sonntag S, Steenackers E, Hendrickx G, Peeters S, De Mare A, Vervaet B, Verhulst A, Mortier G, D’Haese P, Schinke T, Van Hul W (2017) The Lrp4R1170Q homozygous knock-in mouse recapitulates the bone phenotype of sclerosteosis in humans. J Bone Miner Res 32:1739–1749

Article  PubMed  CAS  Google Scholar 

Bullock WA, Hoggatt AM, Horan DJ, Elmendorf AJ, Sato AY, Bellido T, Loots GG, Pavalko FM, Robling AG (2019) Lrp4 mediates bone homeostasis and mechanotransduction through interaction with sclerostin in vivo. iScience 20:205–215

Article  PubMed  PubMed Central  CAS  Google Scholar 

Cosman F, Crittenden DB, Adachi JD, Binkley N, Czerwinski E, Ferrari S, Hofbauer LC, Lau E, Lewiecki EM, Miyauchi A, Zerbini CA, Milmont CE, Chen L, Maddox J, Meisner PD, Libanati C, Grauer A (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375:1532–1543

Article  PubMed  CAS  Google Scholar 

Hendrickx G, Boudin E, Van Hul W (2015) A look behind the scenes: the risk and pathogenesis of primary osteoporosis. Nat Rev Rheumatol 11:462–474

Article  PubMed  Google Scholar 

Chang MK, Kramer I, Huber T, Kinzel B, Guth-Gundel S, Leupin O, Kneissel M (2014) Disruption of Lrp4 function by genetic deletion or pharmacological blockade increases bone mass and serum sclerostin levels. Proc Natl Acad Sci USA 111:E5187-5195

Article  PubMed  PubMed Central  CAS  Google Scholar 

Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, Garner P, Holgate ST, Howells DW, Hurst V, Karp NA, Lazic SE, Lidster K, MacCallum CJ, Macleod M, Pearl EJ, Petersen OH, Rawle F, Reynolds P, Rooney K, Sena ES, Silberberg SD, Steckler T, Wurbel H (2020) Reporting animal research: explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol 18:e3000411

Article  PubMed  PubMed Central  CAS  Google Scholar 

Yorgan TA, Peters S, Jeschke A, Benisch P, Jakob F, Amling M, Schinke T (2015) The anti-osteoanabolic function of sclerostin is blunted in mice carrying a high bone mass mutation of Lrp5. J Bone Miner Res 30:1175–1183

Article  PubMed  CAS  Google Scholar 

Bouxsein ML, Boyd SK, Christiansen BA, Guldberg RE, Jepsen KJ, Muller R (2010) Guidelines for assessment of bone microstructure in rodents using micro-computed tomography. J Bone Miner Res 25:1468–1486

Article  PubMed  Google Scholar 

Albers J, Keller J, Baranowsky A, Beil FT, Catala-Lehnen P, Schulze J, Amling M, Schinke T (2013) Canonical Wnt signaling inhibits osteoclastogenesis independent of osteoprotegerin. J Cell Biol 200:537–549

Article  PubMed  PubMed Central  CAS  Google Scholar 

Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR (1987) Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR histomorphometry nomenclature committee. J Bone Miner Res 2:595–610

Article  PubMed  CAS  Google Scholar 

Hendrickx G, Borra VM, Steenackers E, Yorgan TA, Hermans C, Boudin E, Waterval JJ, Jansen IDC, Aydemir TB, Kamerling N, Behets GJ, Plumeyer C, D’Haese PC, Busse B, Everts V, Lammens M, Mortier G, Cousins RJ, Schinke T, Stokroos RJ, Manni JJ, Van Hul W (2018) Conditional mouse models support the role of SLC39A14 (ZIP14) in hyperostosis cranialis interna and in bone homeostasis. PLoS Genet 14:e1007321

Article  PubMed  PubMed Central  Google Scholar 

Love MI, Huber W, Anders S (2014) Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15:550

Article  PubMed  PubMed Central  Google Scholar 

Ohazama A, Johnson EB, Ota MS, Choi HY, Porntaveetus T, Oommen S, Itoh N, Eto K, Gritli-Linde A, Herz J, Sharpe PT (2008) Lrp4 modulates extracellular integration of cell signaling pathways in development. PLoS ONE 3:e4092

Article  PubMed  PubMed Central  Google Scholar 

Ozcivici E, Luu YK, Adler B, Qin YX, Rubin J, Judex S, Rubin CT (2010) Mechanical signals as anabolic agents in bone. Nat Rev Rheumatol 6:50–59

Article  PubMed  PubMed Central  CAS  Google Scholar 

Papachroni KK, Karatzas DN, Papavassiliou KA, Basdra EK, Papavassiliou AG (2009) Mechanotransduction in osteoblast regulation and bone disease. Trends Mol Med 15:208–216

Article  PubMed  CAS  Google Scholar 

McClung MR, Grauer A, Boonen S, Bolognese MA, Brown JP, Diez-Perez A, Langdahl BL, Reginster JY, Zanchetta JR, Wasserman SM, Katz L, Maddox J, Yang YC, Libanati C, Bone HG (2014) Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med 370:412–420

Article  PubMed  CAS  Google Scholar 

Padhi D, Jang G, Stouch B, Fang L, Posvar E (2011) Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res 26:19–26

Article  PubMed  CAS  Google Scholar